Terms: = Ovarian cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
210 results:
1. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
2. Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer.
Takahashi Y; Taguchi M; Tamura K; Shinohara M; Koyanagi T; Takahashi S; Taneichi A; Takei Y; Saga Y; Fujiwara H
J Obstet Gynaecol Res; 2024 Mar; 50(3):501-507. PubMed ID: 38115203
[TBL] [Abstract] [Full Text] [Related]
3. Expression of egfr, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic and immunological role of FKBP1A in an integrated muti-omics cancers analysis, especially lung cancer.
Zhang Y; Xu H; Pi S; Tan H; Huang B; Chen Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16589-16608. PubMed ID: 37715833
[TBL] [Abstract] [Full Text] [Related]
5. Identification of Genes Associated with prognosis and Immunotherapy Prediction in Triple-Negative Breast cancer via M1/M2 Macrophage Ratio.
Liu J; Deng Y; Liu Z; Li X; Zhang M; Yu X; Liu T; Chen K; Li Z
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512096
[No Abstract] [Full Text] [Related]
6. EFEMP2 upregulates PD-L1 expression via egfr/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract] [Full Text] [Related]
7. Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer.
Hugendieck G; Lettau M; Andreas S; Neumann S; Reinhardt N; Arnold P; Theilig F; Bastian L; Rogmans C; Weimer JP; Flörkemeier I; Wesch D; Arnold N; Maass N; Janssen O; Bauerschlag D; Hedemann N
J Extracell Vesicles; 2023 Jul; 12(7):e12338. PubMed ID: 37408115
[TBL] [Abstract] [Full Text] [Related]
8. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract] [Full Text] [Related]
9. Baicalein suppresses HER2-mediated malignant transformation of HER2-overexpressing ovarian cancer cells by downregulating HER2 gene expression.
Chuang TC; Fang GS; Hsu SC; Lee YJ; Shao WS; Wang V; Lee SL; Kao MC; Ou CC
Environ Toxicol; 2023 Jul; 38(7):1609-1617. PubMed ID: 36988316
[TBL] [Abstract] [Full Text] [Related]
10. Construction of an Immunity and Ferroptosis-Related Risk Score Model to Predict ovarian cancer Clinical Outcomes and Immune Microenvironment.
Wei C; Zhao G; Gao M; Liu Y; Lei P; Cao T
Front Biosci (Landmark Ed); 2023 Jan; 28(1):4. PubMed ID: 36722270
[TBL] [Abstract] [Full Text] [Related]
11. The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.
E Y; Xue H; Zhang CY; Zhao MZ; Zheng HC
Histol Histopathol; 2023 Apr; 38(4):453-465. PubMed ID: 36255176
[TBL] [Abstract] [Full Text] [Related]
12. IQGAP1 is positively correlated with PD-L1 and regulates its expression via mediating STAT proteins phosphorylation.
Chen Y; Mei J; Zhang P; Liu J; Chen L; Wu L; Zhang Y
Int Immunopharmacol; 2022 Jul; 108():108897. PubMed ID: 35729832
[TBL] [Abstract] [Full Text] [Related]
13. Association of Anti-egfr Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
14. Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.
Nikas IP; Lee C; Song MJ; Kim B; Ryu HS
Cancer Med; 2022 Jun; 11(11):2193-2203. PubMed ID: 35212471
[TBL] [Abstract] [Full Text] [Related]
15. Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung cancer.
Porciuncula A; Morgado M; Gupta R; Syrigos K; Meehan R; Zacharek SJ; Frederick JP; Schalper KA
Clin Cancer Res; 2021 Nov; 27(22):6174-6183. PubMed ID: 34518312
[TBL] [Abstract] [Full Text] [Related]
16. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to egfr/MDM2 Inhibitor.
Lai ZY; Tsai KY; Chang SJ; Chuang YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
[TBL] [Abstract] [Full Text] [Related]
17. p85β alters response to egfr inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract] [Full Text] [Related]
18. Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling.
Bolitho C; Moscova M; Baxter RC; Marsh DJ
Mol Cell Endocrinol; 2021 Aug; 533():111338. PubMed ID: 34062166
[TBL] [Abstract] [Full Text] [Related]
19. Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
Lindzen M; Ghosh S; Noronha A; Drago D; Nataraj NB; Leitner O; Carvalho S; Zmora E; Sapoznik S; Shany KB; Levanon K; Aderka D; Ramírez BS; Dahlhoff M; McNeish I; Yarden Y
Oncogene; 2021 May; 40(21):3665-3679. PubMed ID: 33941851
[TBL] [Abstract] [Full Text] [Related]
20. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract] [Full Text] [Related]
[Next]
